Benzinga | Jun 3, 2021 07:56AM EDT

Chardan Capital Maintains Buy on Axcella Health, Lowers Price Target to $10

Chardan Capital analyst Keay Nakae maintains Axcella Health (NASDAQ:AXLA) with a Buy and lowers the price target from $16 to $10.